cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.27054461.v1
title: Association of serum calcium and metabolically healthy obese in US adults: a cross-sectional study

description: The relationship between serum calcium and occurrence of MHO (metabolically healthy obesity) and MUNO (metabolically unhealthy non-obesity) remains unclear, and distinguishing these two phenotypes is difficult within primary healthcare units. This study explores that relationship. This survey included 28590 adults from the National Health and Nutrition Examination Survey (NHANES) 2001–2018. Obesity phenotypes were categorized based on BMI and presence or absence of metabolic syndrome components. Weighted multivariate logistic regression analyses were used to assess the association between serum calcium levels and the obesity phenotype. Restricted cubic spline analysis characterized dose-response relationships, and stratified analyses explored these relationships across sociodemographic and lifestyle factors. The overall prevalence of MHO and MUNO were 2.6% and 46.6%, respectively. After adjusting for covariates, serum calcium exhibited a negative association with MHO [OR (95%): 0.49 (0.36,0.67), <i>p</i> &lt; 0.001], while exhibiting a positive association with MUNO [OR (95%): 1.48 (1.26,1.84), <i>p</i> &lt; 0.001]. Additionally, we found a non-linear association between serum calcium levels and the incidences of MHO and MUNO. Stratified analyses demonstrated a strong negative correlation between serum calcium levels and MHO occurrence across various subgroups. There was no significant interaction between calcium and stratified variables except sex; the association between calcium and the occurrence of MHO was remarkable in female patients. Meanwhile, the predictive ability of serum calcium level for the occurrence of MUNO among all patients was consistent across various subgroups. There was a significant interaction between calcium level and stratified variables based on age, sex, race, and smoking status; the association was remarkable in older (≥ 40 years old), white, none or less smoking, and female patients. A significant correlation was identified between serum calcium levels and MHO or MUNO. The findings suggest that serum calcium levels may serve as an indicator for more accurate assessment and diagnosis of MUNO and MHO, especially among individuals with abdominal obesity. Serum calcium levels exhibited an inverse relationship with metabolically healthy obesity (MHO) and a positive relationship with metabolically unhealthy non-obese (MUNO).A nonlinear association exists between serum calcium levels and the incidence of both MHO and MUNO.Serum calcium has the potential to enhance evaluation and screening for MUNO or MHO in the general US adult population. Serum calcium levels exhibited an inverse relationship with metabolically healthy obesity (MHO) and a positive relationship with metabolically unhealthy non-obese (MUNO). A nonlinear association exists between serum calcium levels and the incidence of both MHO and MUNO. Serum calcium has the potential to enhance evaluation and screening for MUNO or MHO in the general US adult population.
DOI: 10.6084/m9.figshare.25809010
title: Health-related quality of life in patients with generalized pustular psoriasis – a Swedish register study

description: Real-world data on health-related quality of life (HRQoL) in generalized pustular psoriasis (GPP) are scarce and studies have been restricted in terms of instruments used for assessments. To assess generic and dermatology-specific HRQoL of patients with GPP compared with patients with plaque psoriasis using real-world data from the Swedish National Register for Systemic Treatment of Psoriasis. Cross-sectional data from 2006 to 2021 including 7041 individuals with plaque psoriasis without GPP and 80 patients with GPP, of which 19% also had plaque psoriasis. Total scores for the EuroQol-5 Dimensions (EQ-5D) and Dermatology Life Quality Index (DLQI), as well as degree of severity within the instruments’ dimensions/questions, were compared between patient groups. EQ-5D scores were significantly (<i>p</i> &lt; .01) lower (worse) in patients with GPP (mean [standard deviation (SD)] 0.613 [0.346]) vs. patients with plaque psoriasis (mean [SD] 0.715 [0.274]), indicating lower generic HRQoL of patients with GPP. Significantly (<i>p</i> &lt; .01) higher (worse) total DLQI scores were observed for patients with GPP (mean [SD] 10.6 [8.9]) compared with patients with plaque psoriasis (mean [SD] 7.7 [7.1]), with proportionally more patients with GPP having severe (20% vs. 16%) and very severe (17% vs. 8%) problems. The worsened scores for GPP vs. plaque psoriasis were consistent across EQ-5D dimensions and DLQI questions. Individuals with GPP have a considerable impairment in both generic and dermatology-specific HRQoL. The HRQoL was significantly worse in individuals with GPP compared to individuals with plaque psoriasis. The significant HRQoL impairment of GPP shows the potential value of better healthcare interventions for this multisystem disease. The study assessed health-related quality of life (HRQoL) in patients with generalized pustular psoriasis (GPP) compared to patients with plaque psoriasis using real-world data from the Swedish National Register for Systemic Treatment of Psoriasis. The results showed significantly worse HRQoL scores by two different HRQoL instruments (EuroQol-5 Dimensions [EQ-5D] and Dermatology Life Quality Index [DLQI]) in patients with GPP compared to patients with plaque psoriasis. The study indicates that individuals with GPP have a considerable impairment in both generic and dermatology-specific HRQoL.
DOI: 10.6084/m9.figshare.25809010.v1
title: Health-related quality of life in patients with generalized pustular psoriasis – a Swedish register study

description: Real-world data on health-related quality of life (HRQoL) in generalized pustular psoriasis (GPP) are scarce and studies have been restricted in terms of instruments used for assessments. To assess generic and dermatology-specific HRQoL of patients with GPP compared with patients with plaque psoriasis using real-world data from the Swedish National Register for Systemic Treatment of Psoriasis. Cross-sectional data from 2006 to 2021 including 7041 individuals with plaque psoriasis without GPP and 80 patients with GPP, of which 19% also had plaque psoriasis. Total scores for the EuroQol-5 Dimensions (EQ-5D) and Dermatology Life Quality Index (DLQI), as well as degree of severity within the instruments’ dimensions/questions, were compared between patient groups. EQ-5D scores were significantly (<i>p</i> &lt; .01) lower (worse) in patients with GPP (mean [standard deviation (SD)] 0.613 [0.346]) vs. patients with plaque psoriasis (mean [SD] 0.715 [0.274]), indicating lower generic HRQoL of patients with GPP. Significantly (<i>p</i> &lt; .01) higher (worse) total DLQI scores were observed for patients with GPP (mean [SD] 10.6 [8.9]) compared with patients with plaque psoriasis (mean [SD] 7.7 [7.1]), with proportionally more patients with GPP having severe (20% vs. 16%) and very severe (17% vs. 8%) problems. The worsened scores for GPP vs. plaque psoriasis were consistent across EQ-5D dimensions and DLQI questions. Individuals with GPP have a considerable impairment in both generic and dermatology-specific HRQoL. The HRQoL was significantly worse in individuals with GPP compared to individuals with plaque psoriasis. The significant HRQoL impairment of GPP shows the potential value of better healthcare interventions for this multisystem disease. The study assessed health-related quality of life (HRQoL) in patients with generalized pustular psoriasis (GPP) compared to patients with plaque psoriasis using real-world data from the Swedish National Register for Systemic Treatment of Psoriasis. The results showed significantly worse HRQoL scores by two different HRQoL instruments (EuroQol-5 Dimensions [EQ-5D] and Dermatology Life Quality Index [DLQI]) in patients with GPP compared to patients with plaque psoriasis. The study indicates that individuals with GPP have a considerable impairment in both generic and dermatology-specific HRQoL.
DOI: 10.6084/m9.figshare.27087890
title: Expression, potential biological behaviour and clinical significance of MCM3 in pancreatic adenocarcinoma: a comprehensive study integrating high throughput sequencing, CRISPR screening and in-house immunohistochemistry

description: Minichromosome maintenance complex component 3 (MCM3) plays a key role in various tumours. However, it remains largely unknown what the specific role and clinical significance of MCM3 in pancreatic adenocarcinoma (PAAD) are. We integrated high-throughput data from PAAD worldwide to analyse the expression level of MCM3 mRNA. We used immunohistochemistry to analyse MCM3 protein expression levels in 145 cases in the PAAD group and 29 cases in the non-PAAD group. We also mainly analysed the necessity of MCM3 for PAAD growth based on CRISPR screen data. In addition, we used enrichment analysis and protein–protein interaction networks to explore the molecular mechanism of MCM3 in PAAD. We also analysed the correlation between MCM3 expression, components of the immune microenvironment in PAAD tissue and clinical prognosis. In PAAD, we observed for the first time that MCM3 was significantly highly expressed at both the mRNA (SMD = 0.67, 95% CI: 0.38 ∼ 0.96) and the protein level (<i>p</i> &lt; 0.05). The mRNA (AUC = 0.78, 95% CI: 0.74 ∼ 0.81; sensitivity = 0.66, 95% CI: 0.55 ∼ 0.76; specificity = 0.76, 95% CI: 0.67 ∼ 0.84) and protein (AUC = 0.929) expression levels of MCM3 had a good ability to distinguish between PAAD and non-PAAD tissue. There was heterogeneity reflected by the differential expression of MCM3 protein in PAAD cells. MCM3 played an essential role in PAAD growth, through abnormal DNA replication, p53 signalling and cell cycle checkpoints. PAAD with high MCM3 expression was sensitive to c-75, brivanib, flavopiridol and VNLG/124 drugs, with stable molecular docking models. MCM3 is likely to be a critical element in promoting the initiation and growth of PAAD. Flavopiridol may exert its anti-PAAD effect through the interaction between MCM3, classic CDK1 targets in the cell cycle checkpoint and p53 pathway as well as related molecules in other pathways. MCM3 could potentially play a crucial role in promoting the onset and growth of PAAD.There is heterogeneity reflected by the differential expression of MCM3 protein in PAAD cells.The interplay between MCM3, well-established CDK1 targets in the cell cycle checkpoint and p53 pathway, along with relevant molecules in other pathways, may mediate the anti-pancreatic adenocarcinoma (PAAD) effect of flavopiridol. MCM3 could potentially play a crucial role in promoting the onset and growth of PAAD. There is heterogeneity reflected by the differential expression of MCM3 protein in PAAD cells. The interplay between MCM3, well-established CDK1 targets in the cell cycle checkpoint and p53 pathway, along with relevant molecules in other pathways, may mediate the anti-pancreatic adenocarcinoma (PAAD) effect of flavopiridol.
DOI: 10.6084/m9.figshare.27087890.v1
title: Expression, potential biological behaviour and clinical significance of MCM3 in pancreatic adenocarcinoma: a comprehensive study integrating high throughput sequencing, CRISPR screening and in-house immunohistochemistry

description: Minichromosome maintenance complex component 3 (MCM3) plays a key role in various tumours. However, it remains largely unknown what the specific role and clinical significance of MCM3 in pancreatic adenocarcinoma (PAAD) are. We integrated high-throughput data from PAAD worldwide to analyse the expression level of MCM3 mRNA. We used immunohistochemistry to analyse MCM3 protein expression levels in 145 cases in the PAAD group and 29 cases in the non-PAAD group. We also mainly analysed the necessity of MCM3 for PAAD growth based on CRISPR screen data. In addition, we used enrichment analysis and protein–protein interaction networks to explore the molecular mechanism of MCM3 in PAAD. We also analysed the correlation between MCM3 expression, components of the immune microenvironment in PAAD tissue and clinical prognosis. In PAAD, we observed for the first time that MCM3 was significantly highly expressed at both the mRNA (SMD = 0.67, 95% CI: 0.38 ∼ 0.96) and the protein level (<i>p</i> &lt; 0.05). The mRNA (AUC = 0.78, 95% CI: 0.74 ∼ 0.81; sensitivity = 0.66, 95% CI: 0.55 ∼ 0.76; specificity = 0.76, 95% CI: 0.67 ∼ 0.84) and protein (AUC = 0.929) expression levels of MCM3 had a good ability to distinguish between PAAD and non-PAAD tissue. There was heterogeneity reflected by the differential expression of MCM3 protein in PAAD cells. MCM3 played an essential role in PAAD growth, through abnormal DNA replication, p53 signalling and cell cycle checkpoints. PAAD with high MCM3 expression was sensitive to c-75, brivanib, flavopiridol and VNLG/124 drugs, with stable molecular docking models. MCM3 is likely to be a critical element in promoting the initiation and growth of PAAD. Flavopiridol may exert its anti-PAAD effect through the interaction between MCM3, classic CDK1 targets in the cell cycle checkpoint and p53 pathway as well as related molecules in other pathways. MCM3 could potentially play a crucial role in promoting the onset and growth of PAAD.There is heterogeneity reflected by the differential expression of MCM3 protein in PAAD cells.The interplay between MCM3, well-established CDK1 targets in the cell cycle checkpoint and p53 pathway, along with relevant molecules in other pathways, may mediate the anti-pancreatic adenocarcinoma (PAAD) effect of flavopiridol. MCM3 could potentially play a crucial role in promoting the onset and growth of PAAD. There is heterogeneity reflected by the differential expression of MCM3 protein in PAAD cells. The interplay between MCM3, well-established CDK1 targets in the cell cycle checkpoint and p53 pathway, along with relevant molecules in other pathways, may mediate the anti-pancreatic adenocarcinoma (PAAD) effect of flavopiridol.
DOI: 10.15468/dl.4ftc6u
title: Occurrence Download

description: A dataset containing 11 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Mikania bradei B.L.Rob."
 ]
}

 The dataset includes 11 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014550-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14266610
title: Dataset: Green synthesis of 1,3,5-triazine derivatives using a sonochemical protocol

description: Dataset for publication Green synthesis of 1,3,5-triazine derivatives using a sonochemical protocol

converted bio-chromoatographic experiments

 

1) experiment desription

2) chromatographic data
DOI: 10.5281/zenodo.14266611
title: Dataset: Green synthesis of 1,3,5-triazine derivatives using a sonochemical protocol

description: Dataset for publication Green synthesis of 1,3,5-triazine derivatives using a sonochemical protocol

converted bio-chromoatographic experiments

 

1) experiment desription

2) chromatographic data
DOI: 10.15468/dl.sta2w9
title: Occurrence Download

description: A dataset containing 18 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Mikania stenomeres B.L.Rob."
 ]
}

 The dataset includes 18 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014551-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.xnw9mm
title: Occurrence Download

description: A dataset containing 117 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Lulia nervosa (Less.) Zardini"
 ]
}

 The dataset includes 117 records from 49 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014553-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.s8mq6y
title: Occurrence Download

description: A dataset containing 180 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Senecio langei Malme"
 ]
}

 The dataset includes 180 records from 62 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014552-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.39u56r
title: Occurrence Download

description: A dataset containing 264 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Stenella coeruleoalba (Meyen, 1833)",
 "HasCoordinate is true",
 "Geometry POLYGON((-1 37.5, -1 45, 11 45, 11 37.5, -1 37.5))",
 "Year is one of (2020, 2021, 2022, 2023)",
 "Month is one of (May, June, July, August)"
 ]
}

 The dataset includes 264 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014554-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.34740/kaggle/dsv/10088316
title: Daily Public Opinion on Israel-Palestine War
DOI: 10.15468/dl.z6cc6d
title: Occurrence Download

description: A dataset containing 175 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Aedes aegypti (Linnaeus, 1762)",
 "Country is Cuba",
 "Year is greater than or equal to 1500"
 ]
}

 The dataset includes 175 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014557-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.86r3wf
title: Occurrence Download

description: A dataset containing 741 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-5.4823 36.11497,-5.49008 36.11531,-5.49555 36.11274,-5.49243 36.11217,-5.48895 36.11472,-5.48694 36.11404,-5.48173 36.11451,-5.4823 36.11497))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 741 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014556-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.9z6ffb
title: Occurrence Download

description: A dataset containing 4140 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Pyrus pyrifolia (Burm.fil.) Nakai"
 ]
}

 The dataset includes 4140 records from 177 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014559-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.7gry83
title: Occurrence Download

description: A dataset containing 36511 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Ligustrum sinense Lour., Ligustrum nokoensis Masam. & K.Mori, Ligustrum sinense Decne.)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 2000"
 ]
}

 The dataset includes 36511 records from 149 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014558-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14259082
title: High-power single-cycle THz emission from large-area photoconductive emitters at 400 kHz

description: This dataset accompanies the paper "High-power single-cycle THz emission from large-area photoconductive emitters at 400 kHz"

General data acquisition:

THz is generated with the Microstructured large-area photoconductive terahertz emitters at room temperature. The excitation pump power is controlled by a motorized lambda/2-waveplate  in connection with a thin-film polarizer. The bias voltage is generated with a waveform generator (keysight 33500B) in combination with a voltage amplifier (Falco WMA-300). The probe beam for electro-optic sampling (EOS) is guided over an oscillating delay line, having a delay range of approximately 15 ps and a shaking frequency of 10 Hz, leading to 1565 THz traces in over 78 s measurement time.

THz traces were obtained with EOS and a lock-in amplifier for low noise detection. The average power is measured with a pyroelectric power meter (Ophir, 3A-P-THz). The data for Fig.2 are provided in the Excel file "PumpSpotSweep_400kHz_25V". Each sheet name corresponds to the pump spot diameter on the LAE. In each sheet, the column named "pump power (W)" corresponds to optical pump power, and measured THz power after correction is in a column named  "THz corrected". the correction factors consist THz transmission through low pass filters and calibration factor for the THz power meter. In a similar way, data in Fig.3 are provided in an Excel file with the name "Fluence_Vs_BiasVotage". Each sheet name corresponds to the applied bias voltage (peak-to-peak) on the LAE. In each sheet, the column named "pump power (W)" corresponds to optical pump power, and measured THz power after correction is in a column named  "THzCorrected". the correction factor is calculated at explained earlier.

The recorded data via lock-in amplifier are saved in HDF-5 format. The EOS trace in the file name is "150kHz_000", and the dark trace "dark1_150kHz_000". For convenient, the THz and noise trace in the time domain were also extracted in at CSV file.

HDF-5 is an efficient (binary), cross-platform data format and can be read easily by i.e. Python or Matlab. The graphical user interface “HDFView” can be downloaded for free (after registration) from https://www.hdfgroup.org/downloads/hdfview/. It allows to explore the folder structure of an HDF-5 file but is not necessary when using Python or Matlab.

The structure of a single HDF-5 from the uploaded raw data is



A folder called "AI", standing for analog input



The dataset "AI 1" stands for the first analog channel, containing the position of the scanning delay line. The voltage can be converted to “THz time” with a conversion factor, where 20 V corresponds to a 15 ps delay.

The dataset “AI 2”, is a voltage signal from the transimpedance amplifier and is proportional to the THz electric field.




There are additional attributes in the root-folder of the HDF-5 file.